Oppilotech

Oppilotech is a UK biotechnology company that uses systems biology and machine learning to build high-resolution computational models of cells and bacteria.

Its proprietary platform simulates biochemical pathways to identify viable drug targets and generate first-in-class discovery programmes.

The company's primary focus is antimicrobial resistance, with programmes targeting Gram-negative bacterial pathogens, and additional oncology programmes based on cancer cell modelling.

Oppilotech has received funding from CARB-X, Innovate UK, and the Wellcome Trust.